298 related articles for article (PubMed ID: 26398108)
1. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
3. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
6. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
[TBL] [Abstract][Full Text] [Related]
7. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
Garg M; Kanojia D; Mayakonda A; Said JW; Doan NB; Chien W; Ganesan TS; Chuang LS; Venkatachalam N; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Oncotarget; 2017 Jan; 8(5):7521-7532. PubMed ID: 27893412
[TBL] [Abstract][Full Text] [Related]
10. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
12. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
13. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
[TBL] [Abstract][Full Text] [Related]
14. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
15. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract][Full Text] [Related]
16. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
Abeykoon JP; Wu X; Nowakowski KE; Dasari S; Paludo J; Weroha SJ; Hu C; Hou X; Sarkaria JN; Mladek AC; Phillips JL; Feldman AL; Ravindran A; King RL; Boysen J; Stenson MJ; Carr RM; Manske MK; Molina JR; Kapoor P; Parikh SA; Kumar S; Robinson SI; Yu J; Boughey JC; Wang L; Goetz MP; Couch FJ; Patnaik MM; Witzig TE
Blood; 2021 Jan; 137(4):513-523. PubMed ID: 33507295
[TBL] [Abstract][Full Text] [Related]
17. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
18. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
19. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
20. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
